TrialDiabetes, obesity & metabolism2018

Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone.

Jennifer M Trujillo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.